We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

How Has The Kidney Fibrosis Treatment Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market for kidney fibrosis treatment has seen robust growth in the past few years, and it is set to further swell from $6.93 billion in 2024 to $7.58 billion in 2025, implying a compound annual growth rate (CAGR) of 9.4%. The past growth can be credited to factors such as increasing investments in research and development targeted towards fibrosis therapies, augmented government support in managing kidney diseases, heightened patient knowledge about kidney transplants and fibrosis treatment alternatives, improvement in healthcare infrastructure, and a rise in the elderly population.

It is projected that the kidney fibrosis treatment market will experience substantial expansion in the coming years, with its worth estimated to reach $10.78 billion by the year 2029, as it grows at a compound annual growth rate (CAGR) of 11.7%. This anticipated expansion during the forecast period can be tied to the growing rates of chronic kidney ailments, the mounting need for advanced renal fibrosis therapies, increased recognition of the importance of identifying kidney fibrosis at its early stages, the growing use of personalized treatments for kidney disease, and the rising cases of diabetes and hypertension. Significant trends to look out for in the forecast period include advancements in technology for early detection and diagnosis, progression in gene therapy, the integration of technology in telemedicine and remote monitoring, improvements in stem cell therapies, and developments in drug delivery systems.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What Are the Core Growth Drivers Propelling the Kidney Fibrosis Treatment Market Forward?

The escalating occurrence of chronic kidney diseases is anticipated to fuel the expansion of the kidney fibrosis treatment market. Chronic kidney disease (CKD), which commonly results from conditions like diabetes or hypertension, involves the gradual loss of kidney function, leading to the accumulation of waste products in the body. The escalating occurrence of CKD is largely influenced by growing diabetes rates, a condition that harms kidney blood vessels and compromises their filtration capabilities. Kidney fibrosis treatment provides support for CKD patients by addressing kidney tissue scarring, reducing inflammation, and decelerating kidney damage progression, thereby maintaining kidney function. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), stated that it was estimated that approximately 14% of U.S. adults, roughly 35.5 million individuals, are thought to be dealing with chronic kidney diseases. Hence, the escalating occurrence of chronic kidney disease supports the growth of the kidney fibrosis treatment market. As for the stimulation of market growth due to demand for pioneering and personalized treatments, the mounting activities in clinical trials are projected to thrust the expansion of the kidney fibrosis treatment market. Clinical trials are human-based research studies aimed at examining the safety, efficacy, and side effects of medical treatments or interventions. The rise in clinical trials is attributable to the increasing demand for innovative and personalized treatments that require thorough examination for safety and results. Kidney fibrosis treatment aids clinical trials by offering a concentrated area to examine novel anti-fibrotic therapies, thus enabling researchers to assess the efficacy of new medications in the deceleration or reversal of kidney damage. For instance, in November 2023, according to the Association of the British Pharmaceutical Industry, there was a 15% annual increase in the number of participants in industry clinical trials in the UK, moving up from 36,722 participants in 2021-22 to 42,088 in 2022-23. As a result, the escalating clinical trials collectively drive the expansion of the kidney fibrosis treatment market.

What Segment Types Define the Kidney Fibrosis Treatment Market Structure?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests, Kidney Biopsy

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Kidney Fibrosis Treatment Market?

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

View the full report here:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

What Is the Definition of the Kidney Fibrosis Treatment Market?

Kidney fibrosis treatment refers to therapeutic strategies aimed at slowing, halting, or reversing the progression of fibrosis in the kidneys. Kidney fibrosis is the excessive accumulation of extracellular matrix proteins such as collagen, resulting to scarring and functional decline of kidney tissue, commonly associated with chronic kidney disease (CKD).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model